Qyuns Therapeutics Co., Ltd. (HKG:2509)
Hong Kong · Delayed Price · Currency is HKD 16.97
+0.19 (1.13%)
Aug 21, 2026, 3:45 PM HKT
Qyuns Therapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,025 | 806.96 | 158.79 | - | - | - |
Other Revenue | - | - | - | - | 9.66 | 21.35 |
| 1,025 | 806.96 | 158.79 | - | 9.66 | 21.35 | |
Revenue Growth | 219.81% | 408.18% | - | - | -54.74% | - |
Cost of Revenue | 116.41 | 92.55 | 66.6 | - | - | - |
Gross Profit | 908.13 | 714.41 | 92.19 | - | 9.66 | 21.35 |
Selling, General & Admin | 124.45 | 130.4 | 116.85 | 164.59 | 76.6 | 48.8 |
Research & Development | 200 | 253.17 | 334.28 | 364.4 | 257.21 | 151.89 |
Other Operating Expenses | 19.55 | -1.9 | -16.66 | -14.74 | - | - |
Operating Expenses | 349.03 | 384.28 | 434.47 | 514.26 | 333.82 | 200.69 |
Operating Income | 559.1 | 330.13 | -342.28 | -514.26 | -324.16 | -179.34 |
Interest Expense | -18.69 | -19.22 | -23.39 | -16.82 | -18.69 | -17.84 |
Interest & Investment Income | 8.51 | 8.51 | 7.78 | 4.47 | 4.17 | 7.06 |
Currency Exchange Gain (Loss) | -11.2 | -11.2 | 3.89 | -0.43 | 14.46 | -2.72 |
Other Non Operating Income (Expenses) | -2.93 | -2.93 | - | - | -0.06 | -240.18 |
EBT Excluding Unusual Items | 534.79 | 305.28 | -354 | -527.04 | -324.28 | -433.02 |
Gain (Loss) on Sale of Investments | 2.09 | 2.09 | 4.24 | 5.7 | 11.9 | 6.48 |
Pretax Income | 536.88 | 307.37 | -349.76 | -521.33 | -312.38 | -426.54 |
Income Tax Expense | -0.07 | -0.07 | -0.07 | -0.07 | -0.07 | -0.07 |
Earnings From Continuing Operations | 536.95 | 307.44 | -349.69 | -521.26 | -312.31 | -426.47 |
Minority Interest in Earnings | 9.15 | 7.01 | 14.11 | 13.51 | 14.12 | 15.43 |
Net Income | 546.1 | 314.45 | -335.57 | -507.75 | -298.19 | -411.04 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | -112.77 |
Net Income to Common | 546.1 | 314.45 | -335.57 | -507.75 | -298.19 | -298.27 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 226 | 224 | 219 | 206 | 178 | 116 |
Shares Outstanding (Diluted) | 226 | 224 | 219 | 206 | 178 | 116 |
Shares Change | 1.96% | 1.94% | 6.70% | 15.67% | 52.95% | - |
EPS (Basic) | 2.41 | 1.41 | -1.53 | -2.47 | -1.68 | -2.57 |
EPS (Diluted) | 2.41 | 1.41 | -1.53 | -2.47 | -1.68 | -2.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 512.43 | 392.37 | -187.31 | -308.56 | -245.33 | -180.55 |
Free Cash Flow Per Share | 2.26 | 1.75 | -0.85 | -1.50 | -1.38 | -1.55 |
Gross Margin | 88.64% | 88.53% | 58.06% | - | 100.00% | 100.00% |
Operating Margin | 54.57% | 40.91% | -215.55% | - | -3354.95% | -840.05% |
Profit Margin | 53.30% | 38.97% | -211.33% | - | -3086.22% | -1397.13% |
Free Cash Flow Margin | 50.02% | 48.62% | -117.96% | - | -2539.08% | -845.71% |
EBITDA | 589.59 | 360.64 | -311.81 | -484.13 | -295.51 | -155.65 |
EBITDA Margin | 57.55% | 44.69% | -196.36% | - | - | - |
D&A For EBITDA | 30.5 | 30.51 | 30.46 | 30.13 | 28.65 | 23.7 |
EBIT | 559.1 | 330.13 | -342.28 | -514.26 | -324.16 | -179.34 |
EBIT Margin | 54.57% | 40.91% | -215.55% | - | - | - |